Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 1/20 | 0.34 |
| ▸ | ITGB2 | P05107 | 1/20 | 0.34 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.34 |
| ▸ | ITGAV | P06756 | 1/20 | 0.34 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.34 |
| ▸ | ITGA5 | P08648 | 1/20 | 0.34 |
| ▸ | ITGB5 | P18084 | 1/20 | 0.34 |
| ▸ | ITGAL | P20701 | 1/20 | 0.34 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.34 |
| ▸ | CAD | P27708 | 1/20 | 0.32 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9699985 | 0.87 | MCL1 (0.34) | ITGB3ITGB2ITGB1ITGAVITGA2B | |
| SCHEMBL2274342 | 0.85 | KMT2A (0.33) | ITGB3ITGB2ITGB1ITGAVITGA2B | |
| SCHEMBL380941 | 0.85 | KMT2A (0.33) | ITGB3ITGB2ITGB1ITGAVITGA2B | |
| SCHEMBL9699920 | 0.85 | KMT2A (0.33) | ITGB3ITGB2ITGB1ITGAVITGA2B | |
| SCHEMBL9699954 | 0.85 | KMT2A (0.33) | ITGB3ITGB2ITGB1ITGAVITGA2B | |
| SCHEMBL3944202 | 0.82 | CRBN (0.32) | ITGB3ITGB2ITGB1ITGAVITGA2B | |
| SCHEMBL8563469 | 0.79 | ITGB3 (0.35) | ITGB3ITGB2ITGB1ITGAVITGA2B | |
| SCHEMBL4224698 | 0.79 | ITGB3 (0.35) | ITGB3ITGB2ITGB1ITGAVITGA2B | |
| SCHEMBL1162329 | 0.70 | — | — | |
| SCHEMBL1162649 | 0.70 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 139 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026098441-A1 | COMPOSITION AND METHOD FOR CANCER TREATMENT USING POLYPEPTIDE CONJUGATES | SUZHOU SMARTNUCLIDE BIOPHARMACEUTICAL CO., LTD. (CN) | 2026-05-15 | — | — | WO | claimed |
| EP-4683654-A1 | SIRP VARIANTS AND USES THEREOF | Li, Wangzhi (US) | 2026-01-28 | — | — | EP | claimed |
| EP-4396227-B1 | IMPROVED FC SILENCED ANTI-OXMIF ANTIBODIES WITH REDUCED AGGREGATION POTENTIAL AND REDUCED HYDROPHOBICITY | ONCOONE RES & DEVELOPMENT GMBH (AT) | 2025-07-09 | — | — | EP | claimed |
| US-20250129148-A1 | IMPROVED Fc SILENCED ANTI-oxMIF ANTIBODIES WITH REDUCED AGGREGATION POTENTIAL AND REDUCED HYDROPHOBICITY | ONCOONE RESEARCH & DEVELOPMENT GMBH (AT) | 2025-04-24 | — | — | US | claimed |
| WO-2024213119-A1 | PH-SENSITIVE CD47-BINDING DOMAINS AND USES THEREOF | ADAPTOCUE, LLC (US) | 2024-10-17 | — | — | WO | claimed |
| WO-2024193635-A1 | SIRP VARIANTS AND USES THEREOF | LI, Wangzhi (US) | 2024-09-26 | — | — | WO | claimed |
| EP-4396227-A1 | IMPROVED FC SILENCED ANTI-OXMIF ANTIBODIES WITH REDUCED AGGREGATION POTENTIAL AND REDUCED HYDROPHOBICITY | OncoOne Research & Development GmbH (AT) | 2024-07-10 | — | — | EP | claimed |
| CN-118302444-A | Improved Fc-silenced anti-oxMIF antibodies with reduced aggregation potential and reduced hydrophobicity | 翁科奥内研发有限责任公司 | 2024-07-05 | — | — | CN | claimed |
| WO-2023031397-A1 | IMPROVED Fc SILENCED ANTI-oxMIF ANTIBODIES WITH REDUCED AGGREGATION POTENTIAL AND REDUCED HYDROPHOBICITY | ONCOONE RESEARCH & DEVELOPMENT GMBH (AT) | 2023-03-09 | — | — | WO | claimed |
| WO-2022190030-A1 | A TOPICAL FORMULATION FOR THE TREATMENT OF SKIN DISEASES | AVACA PHARMA PRIVATE LIMITED (IN) | 2022-09-15 | — | — | WO | claimed |
| US-9421262-B2 | Compositions and methods for treating dermatological conditions | BIOMED RESEARCH & TECHNOLOGIES, INC. (US) | 2016-08-23 | — | — | US | claimed |
| WO-2011051813-A1 | COMPOSITIONS AND METHODS FOR TREATING DERMATOLOGICAL CONDITIONS | PAUL HARBHAJAN S (US) | 2011-05-05 | — | — | WO | claimed |
| US-20110098229-A1 | COMPOSITIONS AND METHODS FOR TREATING DERMATOLOGICAL CONDITIONS | BIOMED RESEARCH & TECHNOLOGIES, INC. | 2011-04-28 | — | — | US | claimed |
| EP-2016173-A2 | METHODS AND COMPOSITIONS FOR TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS INFECTION WITH CONJUGATED ANTIBODIES OR ANTIBODY FRAGMENTS | Immunomedics, Inc. (US) | 2009-01-21 | — | — | EP | claimed |
| WO-2007134037-A2 | METHODS AND COMPOSITIONS FOR TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS INFECTION WITH CONJUGATED ANTIBODIES OR ANTIBODY FRAGMENTS | IMMUNOMEDICS, INC. (US) | 2007-11-22 | — | — | WO | claimed |
| EP-1411987-A2 | TARGETED POLYMERIC DELIVERY SYSTEMS | Immunomedics, Inc. (US) | 2004-04-28 | — | — | EP | claimed |
| WO-2003011342-A2 | TARGETED POLYMERIC DELIVERY SYSTEMS | IMMUNOMEDICS, INC. (US) | 2003-02-13 | — | — | WO | claimed |
| EP-1098630-A2 | COMPOSITION FOR ENHANCING EPIDERMAL LIPID PRODUCTION | Biomed Research and Technologies, Inc. (US) | 2001-05-16 | — | — | EP | claimed |
| US-6149924-A | FOR TOPICAL APPLICATION | BIOMED RESEARCH & TECHNOLOGIES, INC. (US) | 2000-11-21 | — | — | US | claimed |
| WO-2000004870-A2 | COMPOSITION FOR ENHANCING EPIDERMAL LIPID PRODUCTION | BIOMED RESEARCH AND TECHNOLOGIES, INC. (US) | 2000-02-03 | — | — | WO | claimed |